Zydus partners Medicure to launch cholesterol drug in US
New Delhi: Drug firm Zydus Cadila has entered into a definitive agreement with US-based Medicure International Inc to commercialize its new drug application product pitavastatin magnesium in the US.
"The launch of ZYPITAMAG, which is used to manage cholesterol levels, marks the first branded product launch for Zydus in the US," the company said in a regulatory filing.
Zydus Cadila said as part of this agreement, it will hold the new drug application (NDA) and Medicure will be responsible for the sales and marketing of ZYPITAMAG.
Zydus Cadila has entered into an agreement with Medicure International Inc, a subsidiary of Medicure Inc.
ZYPITAMAG has been approved in strengths of 1 mg, 2 mg, and 4 mg.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd